Axonyx About
Axonyx: AXONYX is a biopharmaceutical company engaged
in the business of acquiring and developing novel post-discovery central nervous
system drug candidates, primarily in areas of memory and cognition. Phenserine
is Axonyx's lead compound in development for the treatment of Alzheimer's Disease
(AD). Phenserine is a potent and selective inhibitor of acetylcholinesterase.
Phenserine has been shown to increase memory and learning in the rat over a wide
therapeutic range. Phenserine
works through two mechanisms: (1) it inhibits the degradation of
the neurotransmitter acetylcholine in the brains of animals, and (2) it
inhibits the production of a toxic form of the beta-amyloid protein in the brain
that is thought to be a cause of the death of brain cells in AD. Note:
Phenserine failed phase III trial for mild to moderate Alzheimer's Disease. The
company has also acquired the patent rights to two additional platform technologies,
the prion and amyloid inhibiting peptides (PIP's and AIP's respectively). The
AIP's (beta-sheet breakers) have the potential to disrupt and/or breakup the toxic
beta-amyloid plaque that surrounds the nerve cells of patients with AD. AXONYX
received a $1 million milestone payment when Serono initiated a Phase I clinical
trial with a beta-sheet breaker peptide for the potential treatment of AD. AXONYX
also has co-inventorship rights to a therapeutic compound named Posiphen
designed for the treatment of AD and other cognitive disorders. Pipeline:
More on Axonyx:
Key
Statistics fo
Axonyx
Phase
III Phenserine Alzheimers
(failed on 2/07/05)
Phase
II Phenserine Alzheimers
Phase
I Phenserine
Alzheimers
Basic Chart
for Axonyx